BAY 57-1293-d4

BAY 57-1293-d4 is intended for use as an internal standard for the quantification of BAY 57-1293 (Item No. 22129) by GC- or LC-MS. BAY 57-1293 is an orally bioavailable helicase-primase inhibitor.1 It inhibits the ATPase activity of herpes simplex virus (HSV) helicase-primase (IC50 = 30 nM). It inhibits HSV replication in Vero cells (IC50 = 20 nM for both HSV-1 and HSV-2) and is also active against porcine and bovine HSV strains (IC50s = 5 and 0.12 μM, respectively). In vivo, oral administration of BAY 57-1293 is effective against HSV-1 and HSV-2 in a lethal challenge model (ED50 = 0.5 mg/kg in mice and rats) and in a zosteriform spread model, at a dose of 15 mg/kg, in mice and Lewis rats.1,2 It is also effective in a guinea pig model of genital herpes and a mouse model of ocular herpes. BAY 57-1293 reduces levels of amyloid-beta (Aβ) and phosphorylated Tau in HSV-1 infected Vero cells.3WARNING This product is not for human or veterinary use.

[1] GERALD KLEYMANN. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease[J]. Nature Medicine, 2002, 8 4: 392-398. DOI: 10.1038/nm0402-392
[2] U. BETZ. Potent In Vivo Antiviral Activity of the Herpes Simplex Virus Primase-Helicase Inhibitor BAY 57-1293[J]. Antimicrobial Agents and Chemotherapy, 2002, 64 1: 1766-1772. DOI: 10.1128/aac.46.6.1766-1772.2002
[3] M.A. WOZNIAK  R. F I  A L Frost. The helicase-primase inhibitor BAY 57–1293 reduces the Alzheimer’s disease-related molecules induced by herpes simplex virus type 1[J]. Antiviral research, 2013, 99 3: Pages 401-404. DOI: 10.1016/j.antiviral.2013.07.003